Drugs / maltose
maltose
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01562626 Background | Sep 2012 → May 2021 | cancer | Anaeropharma Science, Inc. | Suspended | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | maltose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01562626 ↗ |
| Known as | Maltose anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908365 ↗ |
| Known as | Maltose, unspecified form | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908365 ↗ |
| Known as | NSC-760396 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908365 ↗ |
| Modality | Other / unclassified | “10% maltose injection, a sugar that has been shown to enhance the growth and effectiveness of APS001F in animals.” NCT01562626 ↗ |
| Route | Other | “10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.” NCT01562626 ↗ |